These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 17517351

  • 1. Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy.
    Iyengar S, Haas G, Lamba S, Orsinelli DA, Babu GJ, Ferketich AK, Yamokoski L, Periasamy M, Abraham WT.
    J Card Fail; 2007 May; 13(4):304-11. PubMed ID: 17517351
    [Abstract] [Full Text] [Related]

  • 2. Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-alpha expression, and apoptotic death in failing human myocardium.
    D'Ascia C, Cittadini A, Monti MG, Riccio G, Saccà L.
    Eur Heart J; 2006 Jan; 27(2):201-6. PubMed ID: 16291773
    [Abstract] [Full Text] [Related]

  • 3. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders.
    Vanderheyden M, Mullens W, Delrue L, Goethals M, de Bruyne B, Wijns W, Geelen P, Verstreken S, Wellens F, Bartunek J.
    J Am Coll Cardiol; 2008 Jan 15; 51(2):129-36. PubMed ID: 18191736
    [Abstract] [Full Text] [Related]

  • 4. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE).
    Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E.
    Circulation; 2006 Jan 17; 113(2):266-72. PubMed ID: 16401777
    [Abstract] [Full Text] [Related]

  • 5. Clinical predictors of marked improvement in left ventricular performance after cardiac resynchronization therapy in patients with chronic heart failure.
    Mangiavacchi M, Gasparini M, Faletra F, Klersy C, Morenghi E, Galimberti P, Genovese L, Regoli F, De Chiara F, Bragato R, Andreuzzi B, Pini D, Gronda E.
    Am Heart J; 2006 Feb 17; 151(2):477.e1-477.e6. PubMed ID: 16442917
    [Abstract] [Full Text] [Related]

  • 6. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents.
    Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR.
    N Engl J Med; 2002 May 02; 346(18):1357-65. PubMed ID: 11986409
    [Abstract] [Full Text] [Related]

  • 7. Endomyocardial upregulation of beta1 adrenoreceptor gene expression and myocardial contractile reserve following cardiac resynchronization therapy.
    Vanderheyden M, Mullens W, Delrue L, Goethals M, Verstreken S, Wijns W, de Bruyne B, Bartunek J.
    J Card Fail; 2008 Mar 02; 14(2):172-8. PubMed ID: 18325466
    [Abstract] [Full Text] [Related]

  • 8. Repercussion of functional mitral regurgitation on reverse remodelling in cardiac resynchronization therapy.
    Cabrera-Bueno F, García-Pinilla JM, Peña-Hernández J, Jiménez-Navarro M, Gómez-Doblas JJ, Barrera-Cordero A, Alzueta-Rodríguez J, de Teresa-Galván E.
    Europace; 2007 Sep 02; 9(9):757-61. PubMed ID: 17573358
    [Abstract] [Full Text] [Related]

  • 9. Magnetic resonance imaging assessment of reverse left ventricular remodeling late after restrictive mitral annuloplasty in early stages of dilated cardiomyopathy.
    Westenberg JJ, Braun J, Van de Veire NR, Klautz RJ, Versteegh MI, Roes SD, van der Geest RJ, de Roos A, van der Wall EE, Reiber JH, Bax JJ, Dion RA.
    J Thorac Cardiovasc Surg; 2008 Jun 02; 135(6):1247-52; discussion 1252-3. PubMed ID: 18544363
    [Abstract] [Full Text] [Related]

  • 10. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
    Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Török T, Linde C, REVERSE Study Group.
    J Am Coll Cardiol; 2009 Nov 10; 54(20):1837-46. PubMed ID: 19800193
    [Abstract] [Full Text] [Related]

  • 11. Marked improvement in left ventricular function and significant reverse left ventricular remodeling within 3 months of cardiac resynchronization therapy in patients with dilated cardiomyopathy.
    Funck RC, Koelsch S, Waldhans S, Prinz H, Grimm W, Moosdorf R, Maisch B.
    Pacing Clin Electrophysiol; 2005 Jan 10; 28 Suppl 1():S5-7. PubMed ID: 15683524
    [Abstract] [Full Text] [Related]

  • 12. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up.
    Ypenburg C, van Bommel RJ, Borleffs CJ, Bleeker GB, Boersma E, Schalij MJ, Bax JJ.
    J Am Coll Cardiol; 2009 Feb 10; 53(6):483-90. PubMed ID: 19195605
    [Abstract] [Full Text] [Related]

  • 13. Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and gender.
    Cappola TP, Harsch MR, Jessup M, Abraham WT, Young JB, Petersen-Stejskal S, Plappert T, St John Sutton M.
    J Card Fail; 2006 Apr 10; 12(3):182-8. PubMed ID: 16624682
    [Abstract] [Full Text] [Related]

  • 14. Myocardial contractile reserve predicts improvement in left ventricular function after cardiac resynchronization therapy.
    Ypenburg C, Sieders A, Bleeker GB, Holman ER, van der Wall EE, Schalij MJ, Bax JJ.
    Am Heart J; 2007 Dec 10; 154(6):1160-5. PubMed ID: 18035090
    [Abstract] [Full Text] [Related]

  • 15. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy.
    Barton PJ, Felkin LE, Birks EJ, Cullen ME, Banner NR, Grindle S, Hall JL, Miller LW, Yacoub MH.
    Circulation; 2005 Aug 30; 112(9 Suppl):I46-50. PubMed ID: 16159864
    [Abstract] [Full Text] [Related]

  • 16. Antiarrhythmic effect of reverse ventricular remodeling induced by cardiac resynchronization therapy: the InSync ICD (Implantable Cardioverter-Defibrillator) Italian Registry.
    Di Biase L, Gasparini M, Lunati M, Santini M, Landolina M, Boriani G, Curnis A, Bocchiardo M, Vincenti A, Denaro A, Valsecchi S, Natale A, Padeletti L, InSync/InSync ICD Italian Registry Investigators.
    J Am Coll Cardiol; 2008 Oct 28; 52(18):1442-9. PubMed ID: 19017510
    [Abstract] [Full Text] [Related]

  • 17. Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy.
    Ajijola OA, Nandigam KV, Chabner BA, Orencole M, Dec GW, Ruskin JN, Singh JP.
    Am J Cardiol; 2008 May 01; 101(9):1371-2. PubMed ID: 18435975
    [Abstract] [Full Text] [Related]

  • 18. Amiodarone improves cardiac sympathetic nerve function to hold norepinephrine in the heart, prevents left ventricular remodeling, and improves cardiac function in rat dilated cardiomyopathy.
    Tachikawa H, Kodama M, Watanabe K, Takahashi T, Ma M, Kashimura T, Ito M, Hirono S, Okura Y, Kato K, Hanawa H, Aizawa Y.
    Circulation; 2005 Feb 22; 111(7):894-9. PubMed ID: 15710769
    [Abstract] [Full Text] [Related]

  • 19. Exercise stress echocardiography is superior to rest echocardiography in predicting left ventricular reverse remodelling and functional improvement after cardiac resynchronization therapy.
    Rocchi G, Bertini M, Biffi M, Ziacchi M, Biagini E, Gallelli I, Martignani C, Cervi E, Ferlito M, Rapezzi C, Branzi A, Boriani G.
    Eur Heart J; 2009 Jan 22; 30(1):89-97. PubMed ID: 18987095
    [Abstract] [Full Text] [Related]

  • 20. Decreased myocardial chromogranin a expression and colocalization with brain natriuretic peptide during reverse cardiac remodeling after ventricular unloading.
    Wohlschlaeger J, von Winterfeld M, Milting H, El Banayosy A, Schmitz KJ, Takeda A, Takeda N, Azhari P, Schmid C, August C, Schmid KW, Baba HA.
    J Heart Lung Transplant; 2008 Apr 22; 27(4):442-9. PubMed ID: 18374882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.